Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal, shared a post on X:
“Just out! AQUILA data in smoldering myeloma by IMWG 2020 SMM risk groups.
Daratumumab is FDA and EMA-approved for high-risk smoldering myeloma
See the difference in the 5-year rate of progression to Active Myeloma: Dara versus Observation.”
Rahul Banerjee, Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington, shared this post, adding:
“While HR-SMM will no doubt be defined very differently in 10 years with the rise of genomics, this is amazing validation both of:
- current 20/2/20/HR criteria
- dara as an emerging norm to knock #MMsm risk down in HR-SMM
Congrats.”
More posts featuring Vincent Rajkumar.